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Abstract
Background: While different ways of presenting treatment effects can affect health care decisions, little is known about
which presentations best help people make decisions consistent with their own values. We compared six summary statistics
for communicating coronary heart disease (CHD) risk reduction with statins: relative risk reduction and five absolute
summary measures—absolute risk reduction, number needed to treat, event rates, tablets needed to take, and natural
frequencies.
Methods and Findings: We conducted a randomized trial to determine which presentation resulted in choices most
consistent with participants’ values. We recruited adult volunteers who participated through an interactive Web site.
Participants rated the relative importance of outcomes using visual analogue scales (VAS). We then randomized participants
to one of the six summary statistics and asked them to choose whether to take statins based on this information. We
calculated a relative importance score (RIS) by subtracting the VAS scores for the downsides of taking statins from the VAS
score for CHD. We used logistic regression to determine the association between participants’ RIS and their choice. 2,978
participants completed the study. Relative risk reduction resulted in a 21% higher probability of choosing to take statins
over all values of RIS compared to the absolute summary statistics. This corresponds to a number needed to treat (NNT) of 5;
i.e., for every five participants shown the relative risk reduction one additional participant chose to take statins, compared to
the other summary statistics. There were no significant differences among the absolute summary statistics in the association
between RIS and participants’ decisions whether to take statins. Natural frequencies were best understood (86% reported
they understood them well or very well), and participants were most satisfied with this information.
Conclusions: Presenting the benefits of taking statins as a relative risk reduction increases the likelihood of people
accepting treatment compared to presenting absolute summary statistics, independent of the relative importance they
attach to the consequences. Natural frequencies may be the most suitable summary statistic for presenting treatment
effects, based on self-reported preference, understanding of and satisfaction with the information, and confidence in the
decision.
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For patients, health care professionals, and policy makers to
make informed choices about health care, they must have
information about the effects of interventions that is valid and
understandable. The manner in which this information is
presented affects choice [1,2]. The goal of the Health Information
Project: Presentation Online (HIPPO) is to evaluate alternative
ways of presenting research evidence in order to improve
communication of information about the effects of health care
and to facilitate clinical decisions that are consistent with patient
values. (‘‘Values’’ here refers to the relative importance of the
desirable and undesirable effects of an intervention.)
Systematic reviews [1,2] have found that use of relative risk
reduction (RRR) to represent the effect of treatment results in
individuals perceiving a larger treatment effect and being more
likely to decide in favor of treatment compared with the use of
absolute risk reduction (ARR) or the number needed to treat
(NNT) [1]. In studies to find a minimally important difference,
ARR produced 20% larger differences in the medians than NNT
(25% versus 5%). The same review found that presenting the
percentage of people experiencing outcomes with and without
treatment resulted in more accurate perceptions than RRR when
baseline risk was also provided. Others have advocated summary
measures that have been less well studied, such as the tablets
needed to take (TNT) [3] and ‘‘natural frequencies’’ (NF), i.e., raw
observations that have not been transformed into percentages.
Gigerenzer and others [4–7] advocate this format as a way of
facilitating correct decisions, especially in diagnostics, among
physicians as well as lay people. Hollnagel proposed a similar
summary statistic, referred to as whole numbers [8].
There is a large literature that addresses how different
presentations, including positive versus negative framing, different
summary statistics, and different formats (numeric, verbal, or
graphical) influence understanding, perceptions, and decisions;
and how information about risk is used in decisions [1–16].
However, to our knowledge, there are no studies investigating the
relationship between the summary statistic used and the extent to
which decisions are consistent with individuals’ values, apart from
our pilot study [17].
Thus, we designed this study to assess the extent to which the
use of different summary statistics affects choices about using
statins to reduce the risk of coronary heart disease (CHD). We
chose this decision because it is common, important, familiar to
many, and because high-quality evidence is available about the
benefits and downsides of statins [18]. It is a ‘‘preference sensitive’’
decision that is affected by patients’ values [19]. Thus, among
people with the same hypothetical or real risk of CHD, one would
expect some degree of correlation between how important the
desirable and undesirable consequences of taking statins are to
them and the likelihood that they would decide to take statins. In
other words, one would expect that people for whom the benefits
of taking statins were less important and the downsides more
important would be less likely, on average, to decide to take them
than people for whom the benefits were more important and the
downsides were less important.
Methods
Study Design
The CONSORT checklist and the protocol for this study are
available as supporting information; see Text S1 and S2.
This study was an Internet-based randomized trial (Text S3) in
which participants were randomized to one of six summary
statistics presenting information about CHD risk reduction
associated with statin use (Text S4). A pilot study of similar design
with 770 participants in 2002 informed the final design of this trial
[17]. Data from the pilot study are not included in this report.
Recruitment, Eligibility, and Allocation
The study and its Web site link were advertised to the public in
Norway and North America through traditional media (radio, TV,
flyers in public spaces including physician offices) and through
online ads in Web portals and health-related Web sites. To
encourage participation, we offered prospective participants the
option to take part in a lottery for a $100 gift certificate and to
receive study results.
Only complete responses from people who reported being 18
years or older, and that they were answering for the first time,
were included in the analysis.
We randomized participants to one of the six presentations
upon log-on by block-randomization (Text S4), using a looped
sequence of 600 presentation assignments consisting of 100 blocks
of six that was generated on http://www.randomization.com.
Data Collection
After choosing to log onto either the Norwegian or English-
language version of the study Web site, participants received
information about the study and gave informed consent to
participate. Then, participants reviewed a hypothetical scenario
involving themselves as patients with elevated cholesterol whose
doctors had offered them the option of taking pills (statins) to lower
blood cholesterol levels to reduce their risk of CHD (Figure 1).
They learned that they had to take a pill each day and incur an
out-of-pocket cost for the pills of US $50 (400 NOK) per month.
Then participants reported the relative importance they
assigned to getting CHD, to a monthly increase of US $50 in
health care costs, and to having to take a pill every day, using a
horizontal 100-point visual analogue scale (VAS) with ‘‘No
problem’’ and ‘‘Very difficult’’ as the lower and upper anchors.
Participants then considered the effectiveness of statins in
reducing the risk of CHD using their randomly assigned summary
statistic (Figure 2). The summary statistics reflected a 10-year
CHD risk of 6% without statins (estimated risk for a person
without other risk factors than a high cholesterol level [20]) and
the 30% relative reduction in the risk of CHD with statins [21].
Participants then had to decide whether or not to take statins.
They could access additional explanations of terms such as
‘‘angina’’ and ‘‘heart attack’’ using hyperlinks in the text (Figure 3)
or navigate back to previously answered screens and change their
answers, but could not return after having made a decision.
After making this decision, participants reported, using a 5-
point scale where 5 was the highest rating, on their confidence in
their decision and understanding of and satisfaction with the
information. Participants then completed a numeracy assessment
(Figure 4), a salience questionnaire (to measure how relevant or
important the hypothetical scenario was likely to be to the
participants) (Figure 5), and reported sociodemographic data.
Then, they reviewed all six summary statistics and were asked
which one they preferred.
Analysis
We calculated a relative importance score (RIS) for each
participant by subtracting from her VAS score for CHD the sum
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a pill every day. We expected that higher RIS would be correlated
with an increased likelihood of deciding to start taking statins.
The trial sought to test, in terms of concordance between
decisions and RIS values, the following three hypotheses, based on
the results of a pilot study [17]:
Figure 1. Introduction to the scenario prior to eliciting values.
doi:10.1371/journal.pmed.1000134.g001
Figure 2. One of six presentations to which participants were randomized after eliciting values.
doi:10.1371/journal.pmed.1000134.g002
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statins across RIS values compared to the absolute summary
statistics.
2. The slope of the log odds of ARR is greater than the slope of
the other absolute summary statistics.
3. The concordance between decisions and values for the event
rate (ER) is less than for the other absolute summary statistics;
i.e.thattheslope fortherelationship betweenRISvaluesand the
log odds of deciding to take statins is not significantly different
from zero for ER (indicating that decisions were independent of
the participants’ elicited values), whereas it is positive (consistent
with what would be predicted) and significantly different from
zero for the other absolute summary statistics.
In order to evaluate the effects of the different summary
statistics on the decision to start statins, taking into account each
participant’s RIS, we used the following logistic regression model:
logit D ðÞ ~b0 z b1gGg zb2S z b3gGg   S; g~1...6
where D is the decision to go to take statins or not, G is the
presentation group, S is the RIS value, and G*S is the interaction
between the presentation and the RIS value. To make inferences
about the response within each group and for the comparisons of
groups we used dummy variable coding with reference parame-
terization for the presentation groups, i.e., directly estimating the
difference in the effect of each nonreference level compared to the
effect of the reference level. We used Wald tests to compare the p-
values and confidence intervals (CIs) from the logistic regression
and Chi-square tests to compare frequenices. The model was also
explored by including numeracy and salience as covariates.
We used the model without covariates to test the three
hypotheses based on the results of our pilot study [17] by (1)
comparing the log odds of RRR to the log odds of the pooled
absolute summary statistics for the RIS value at which the
predicted log odds was zero (i.e. odds=1) for the pooled summary
statistics; (2) comparing the slope of the log odds of ARR to the
slope of the pooled absolute summary statistics (excluding ARR),
and (3) comparing the slope for the ER group to zero and testing
for a difference in slope between ER and the slope of the pooled
summary statistics excluding ER. Thus, we used a Bonferroni
correction for four comparisons to adjust the confidence intervals
for these analyses corresponding to an overall significance level of
0.05 (i.e. 0.05/4=0.0125) although the sample size estimates were
based on three comparisons.
We performed additional comparisons for the difference in log
odds at the median, 1st, and 3rd quartile values for RIS, and we
compared the slope for the ER group to the slope for the pooled
absolute summary statistics group (excluding ER) We did not
adjust the 95% CIs or p-values for these or other comparisons.
They should be interpreted with caution due to multiple testing
since no assessment of their power was made in the protocol.
Sample Size
Using data from the pilot study, we estimated we would need
about 750 to 800 participants per group to achieve 80% power to
test each one of the three hypotheses at 0.0167 alpha level (after
applying a Bonferroni correction).
Ethics
The protocol was reviewed and approved by the ethics
committee of the University at Buffalo Medical School, Buffalo,
Figure 3. Examples of hypertext links describing a heart attack and angina.
doi:10.1371/journal.pmed.1000134.g003
Figure 4. Numeracy assessment.
doi:10.1371/journal.pmed.1000134.g004
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interface, having been given information about the study and told
that they could quit at any time and request that their data be
deleted. Contact information that some participants supplied in
order to request the study results or to participate in the lottery was
stored in a separate database that was not linkable with study data.
Results
The study recruited 2,978 eligible participants between June
2003 and July 2005 (Table 1). We decided to stop recruitment
prior to achieving the intended sample size after multiple efforts to
encourage participation over two years. We did not look at the
results prior to deciding to stop the study. The six groups were
similar, with respect to sex, age, years of education, salience of the
scenario, and their elicited values. Most respondents were from
USA (42%) and Norway (26%). Seventy-three percent of the
participants chose the English language version of the Web site.
Numeracy varied across the six groups from 65% that answered
both questions correctly in the RRR group to 75% in the TNT
and NF groups.
The most common ways in which participants reported finding
out about the study were a link on another Web site (32%), an
email invitation (27%), and a link to the study sent by a friend
(18%). Fifty-nine percent of the participants were women, 54%
were between 40 and 59 years old, and 63% had 17 or more years
of education. Seventy-one percent answered both questions
assessing numeracy correctly, and the scenario had low or no
salience for 68%, based on their experience with CHD and
hypercholesterolemia.
The participants’ preferred presentation was natural frequencies
(31%) closely followed by RRR (30%). Event rates were preferred
by 20%, NNT by 10%, ARR by 5%, and TNT by 3%.
Decisions in Relation to Values
There was a significantly larger proportion in the RRR group
that decided to start taking statins (74%) than in the ‘‘absolute’’
summary statistics groups (range 51% to 56%) (Table 2).
Participants in all groups were less likely to take statins when the
relative importance score (RIS) was lower and more likely when it
was higher (Figure 6). There were no differences in the association
between RIS and the likelihood of taking statins across the five
absolute summary statistics, including event rates (Table 3).
The testing of the three main hypotheses gave the following results:
1. The difference in log odds of RRR versus the pooled absolute
summary statistics at RIS=12.3 (the point at which the
predicted log odds was zero [odds=1] for the pooled absolute
statistics) was 0.88 (p,0.0001; odds ratio=2.4; adjusted 95%
CI 1.8 to 3.2). The odds of the RRR group choosing to take
Figure 5. Salience questionnaire.
doi:10.1371/journal.pmed.1000134.g005
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Category Subcategory RRR ARR NNT ER TNT NF Overall
n=508 n=505 n=484 n=476 n=512 n=493 n=2,978
Women
a 58.3 58.8 62.6 61.6 56.8 56.8 59.1
Age
a 18–39 37.2 35.5 36.5 32.5 38.9 36.3 36.2
40–59 53.3 53.9 54.3 56.9 50.6 51.9 53.5
$60 9.5 10.7 9.1 10.5 10.5 11.7 10.4
Years of education
a #8 y 1.6 2.2 1.7 1.9 2.1 2.4 2.0
9–12 y 7.3 7.9 5.6 5.7 6.4 6.5 6.6
13–16 y 27.6 26.9 30.2 28.6 28.5 29.8 28.6
$17 y 63.6 63.0 62.6 63.9 62.9 61.3 62.9
Country of residence
a Canada 15 12 13 15 10 13 12.4
Germany 1 1 1 0 0 0 0.6
Norway 29 26 29 23 25 30 26.5
US 40 36 38 43 42 40 41.5
O t h e r 1 52 41 91 82 21 8 1 9 . 0
Language
a English 72 74 71 78 74 71 73.4
Norwegian 28 26 29 22 26 29 26.6
Numeracy
a 2 correct answers 64.6 67.7 73.1 71.6 75.0 74.8 71.1
1 correct answer 30.1 28.1 22.1 23.5 20.1 20.5 24.1
0 correct answers 5.3 4.2 4.8 4.8 4.9 4.7 4.8
Salience score
a 4 (high salience) 4.5 5.0 4.3 3.4 5.5 3.9 4.4
3 2.4 1.4 2.7 1.5 2.0 2.8 2.1
2 25.4 25.1 24.4 27.7 23.4 26.0 25.3
1 (low salience) 60.8 61.8 65.5 62.2 63.5 60.4 62.4
0 (no salience) 6.9 6.7 3.1 5.3 5.7 6.9 5.8
Values (on 100-point
VAS)
b
CHD 80.7 (21) 78.5 (23) 79.7 (21) 80.1 (21) 79 (21.8) 78.8 (23) 79.5 (22)
Cost 30.2 (26) 32.1 (28) 33.3 (27) 31.1 (27) 31 (27) 29.7 (27) 31.2 (27)
Pill taking 21.4 (23) 24.3 (26) 23.4 (26) 22.1 (24) 24.2 (24) 23.3 (25) 23.1 (25)
RIS 29.1 (44) 22.2 (49) 23 (47) 27 (48) 23.8 (48) 25.7 (47) 25.1 (47)
aData presented as percentages of n in a given column.
bData presented as mean (standard deviation) for a given presentation group.
doi:10.1371/journal.pmed.1000134.t001
Table 2. Decisional outcomes.
Outcome RRR ARR NNT ER TNT NF Overall p-Value
a
Decided to start taking statins, n (%) 376 (74) 256 (51) 267 (55) 252 (53) 284 (55) 256 (52) 1,691 (57) ,0.001
Understanding of information, median
(IQR)
4 (4,5) 4 (3, 5) 4 (4,5) 4 (4,5) 4 (4,5) 5 (4,5) 4 (4,5)
High rate (4 or 5 out of 5), n (%) 394 (78) 368 (73) 369 (76) 272 (78) 386 (75) 422 (86) 2,310 (78) 0.002
Satisfaction with information, median
(IQR)
3 (2, 4) 3 (2, 4) 3 (2, 4) 3 (2, 4) 3 (2, 4) 3 (2, 4) 3 (2, 4)
High rate (4 or 5 out of 5), n (%) 163 (32) 158 (31) 157 (32) 150 (32) 145 (28) 201 (41) 974 (33) 0.001
Confidence in decision, median (IQR) 4 (3, 5) 4 (3, 4) 4 (3, 4) 4 (3, 4) 4 (3, 4) 4 (3, 4) 4 (3, 4)
High rate (4 or 5 out of 5), n (%) 317 (62) 287 (57) 270 (56) 282 (60) 302 (62) 305 (62) 1,763 (59) 0.62
ap-Values from Chi-square tests without corrections for multiple testing.
IQR, interquartile range.
doi:10.1371/journal.pmed.1000134.t002
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st
and 3
rd quartiles (Table 4) corresponding to differences of 20%
to 21% in the proportions of participants choosing to take
statins (Table 3).
2. The difference in the slope of the estimated log odds of ARR to
the slope of the pooled absolute summary statistics (excluding
ARR) was 0 (p=0.4, adjusted 95% CI 20.008 to 0.004).
3. The slope of the log odds for the ER group was statistically
significantly different from zero (b=0.013, adjusted 95% CI
0.007 to 0.018) (Table 3), as it also was for the slope for the
pooled absolute summary statistics group excluding ER
(b=0.0105, adjusted 95% CI 0.009 to 0.013). There was no
significant difference between them: point estimate 0 (p=0.3,
adjusted 95% CI 20.004 to 0.008).
There were few responses for the salience categories of 0, 3, and
4, and few responders with no correct numeracy answers. We
therefore pooled and renamed the categories of salience: ‘‘Low
salience (0, 1),’’ ‘‘Some or high salience (2, 3, and 4)’’; and
Figure 6. Likelihood of deciding to start taking statins in relation to RIS.
doi:10.1371/journal.pmed.1000134.g006
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these covariates into the model. Salience was nonsignificant
(p=0.4). Although numeracy was significant (p=0.01), it had a
minor impact on the effect estimates and the standard error. The
c-statistic for the overall model including covariates compared to
the model without covariates was the same (c=0.671).
Understanding and Satisfaction
In terms of understanding, 86% reported they understood NFs
well or very well (Table 2). Confidence in the decision was not
different across randomized groups (p=0.62). Across all partici-
pants, confidence in the decision was associated with the decision
to start statins (p,0.0001). Among those deciding to take statins
65% scored their confidence as 4 or 5 (anchored as ‘‘extremely
confident’’ at a score of 5) compared to 51% among those who
decided not to take statins.
The NF group was the most satisfied with the risk information
that they had initially received (41% rated their satisfaction as 4 or
5 anchored as ‘‘extremely satisfied’’ at a score of 5); least satisfied
were the TNT and the ARR groups (28% rated their satisfaction
as 4 or 5) (Table 2). Across all participants, satisfaction in the risk
information was associated with deciding to take statins (p,0.001).
Discussion
There was a clear relationship between participants’ summary
relative value scores expressed as RIS and the choices that they
made across all summary statistics; i.e., as RIS increased, the
likelihood of choosing to start statins increased, as would be
expected for a preference sensitive decision. RRR resulted in the
largest proportion of participants deciding to start statins
compared to the absolute summary statistics. Participants in the
RRR group were more likely to decide to start statins at all values
of RIS than participants in the absolute summary statistic groups.
The increased probability to choose to start statins in the RRR
group is consistent with conclusions from other studies and
supports the contention that RRR is a more persuasive summary
statistic [1,2,13–16].
This is the first study of which we are aware that shows that
people are more likely to be persuaded when presented with a
relative summary statistic regardless of their values. The findings of
this study confirm the results of our pilot study [17] with respect to
RRR resulting in participants being more likely to decide to take
statins regardless of their values. The findings did not support
either of the two other hypotheses generated from the results of
our pilot study. ARR did not result in a steeper slope of the
estimate of the likelihood (log odds) of deciding to take statins
relative to participants’ RIS values. Event rates did not result in
decisions disassociated from values and, in fact, produced an
estimate that did not differ from the other absolute summary
statistics.
In contrast to the pilot, where the majority (52%) preferred
RRR, only 30% preferred RRR in this study and NF were
preferred by 31% (compared to 25% in the pilot). In both studies,
few participants preferred TNT (3% and 1% in this and the pilot
study respectively) and ARR (5% and 4%). NNT was preferred by
more participants in this study (10%) than in the pilot (4%).
Despite a 2-year recruitment period, the estimated sample size
requirement was not met. This problem of recruiting participants to
Table 3. Likelihood of deciding to take statins in relation to values (RIS).
Presentation Group
Slope (beta)
(95% CI) 1
st quartile RIS=21 Median RIS=31 3
rd quartile RIS=60
Odds (95% CI)
Predicted %
‘‘take’’ Odds (95% CI)
Predicted %
‘‘take’’ Odds (95% CI)
Predicted %
‘‘take’’
RRR 0.015 (0.011–0.020) 1.97 (1.57–2.47) 66.3 (61.0–71.2) 3.23 (2.60–4.00) 76.3 (72.2–80.0) 5.06 (3.80–6.73) 83.5 (79.2–87.1)
ARR 0.009 (0.006–0.013) 0.82 (0.67–1.01) 45.2 (40.2–50.2) 1.11 (0.93–1.33) 52.7 (48.1–57.2) 1.46 (1.16–1.84) 59.4 (53.8–64.8)
NNT 0.010 (0.006–0.015) 0.96 (0.78–1.18) 49.1 (43.9–54.2) 1.35 (1.12–1.63) 57.4 (52.8–61.9) 1.83 (1.44–2.32) 64.6 (59.0–69.9)
ER 0.013 (0.007–0.018)
a 0.79 (0.63–0.98) 44.0 (38.6–49.6) 1.18 (0.98–1.43) 54.2 (49.5–58.8) 1.71 (1.36–2.16) 63.1 (57.6–68.3)
TNT 0.011 (0.007–0.015) 0.96 (0.78–1.17) 48.9 (43.8–54.0) 1.36 (1.13–1.63) 57.5 (53.0–61.9) 1.86 (1.47–2.34) 65.0 (59.6–70.1)
NF 0.011 (0.007–0.016) 0.79 (0.64–0.99) 44.3 (39.0–49.6) 1.15 (0.95–1.38) 53.4 (48.8–57.9) 1.60 (1.27–2.01) 61.5 (55.9–66.7)
Pooled absolute
statistics
0.011 (0.009–0.013) 0.86 (0.79–0.95) 46.4 (44.0–48.7) 1.23 (1.13–1.33) 55.1 (53.0–57.1) 1.68 (1.52–1.87) 62.7 (60.3–65.1)
Pooled absolute
statistics except ARR
0.011 (0.009–0.013) 0.87 (0.79–0.97) 46.7 (44.0–49.3) 1.26 (1.15–1.38) 55.7 (53.4–57.9) 1.74 (1.55–1.96) 63.6 (60.8–66.2)
Predicted %=proportion deciding to take antihypertensive medication based on logistic regression.
aAlpha=0.0125.
doi:10.1371/journal.pmed.1000134.t003
Table 4. Comparisons.
1
st quartile RIS=21 Median RIS=31 3
rd quartile RIS=60
RRR versus pooled absolute statistics 2.27 (1.78–2.91) 2.63 (2.09–3.32) 3.00 (2.22–4.07)
ARR versus pooled absolute statistics except ARR 0.94 (0.75–1.18) 0.89 (0.72–1.09) 0.84 (0. – 1.08)
Data are given as odds ratio (95% CI).
doi:10.1371/journal.pmed.1000134.t004
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randomization worked well, generating six comparable groups.
Applicability of the Findings
We used a variety of strategies to recruit a convenience sample
of participants, including placing links on other Web sites, sending
email invitations, encouraging people to send the link to friends,
and sending messages to discussion lists. Therefore, there is not a
sampling frame from which participants were drawn to which we
can compare them. The participants, however, had a relatively
high level of education and it is uncertain that the findings are
applicable to populations with less education [2,17]. It is also
uncertain to what extent results from the hypothetical scenario
used in this study apply to actual decisions [13,23], to personal
communication [13], to other populations, or to decisions with
higher risk levels.
While the results of Internet-based studies such as this one likely
apply to printed as well as electronic information, they may not
apply to personal communication, when it is possible to interact
and adapt the presentation of information. The influence of how
information is presented on decision making may also vary in
relation to the salience of the scenario to decision makers [17,24]
and to their level of numeracy [17,25], although neither
significantly modified our results (data not shown).
Conclusions
Presentation of the RRR increases the likelihood of people
accepting treatment over that of absolute summary statistics,
independent of the relative importance they attach to the
consequences. We did not find important differences in the
relationship between decisions and values among the five absolute
summary statistics we tested. However, natural frequencies may be
preferable, based on self-reported preference, understanding and
satisfaction with the information, and confidence in decision. This
result supports the advice of others that natural frequencies should
be the preferred summary statistic for decision aids and other risk
communication tools [4–7].
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Background. People often have to make decisions about
their health care. Ideally, all the health care decisions that a
person makes should be those best suited to his or her
personal circumstances and expectations. Take, for example,
someone with a high amount of cholesterol (a type of fat) in
his or her blood. Because this condition increases the
chances of developing potentially fatal coronary heart
disease (CHD), such a person will often be advised by his
or her doctor to take statins to reduce blood cholesterol
levels. However, the person needs to consider both the
benefits and downsides of this course of action. Can he or
she afford to pay for statins, if their health care system
requires him or her to? Does the person want to take a pill
every day that might cause some side effects? That is, the
person has to consider his or her ‘‘values’’—the relative
desirability of all the possible outcomes of taking statins—
before deciding whether to follow his or her doctor’s advice.
Why Was This Study Done? It is well known that how
information is presented to patients about treatment
options and their consequences affects the choices that
they make. For example, patients who are told that a drug
will halve their chances of developing a disease (a 50%
relative risk reduction) are more likely to decide to take that
drug than those who are told it will reduce their absolute
(actual) risk of developing the disease from 4% to 2%. Less is
known, however, about which presentations of treatment
effects best help people to make decisions that are
consistent with their own values. In 2002, therefore, a
series of internet-based randomized trials (studies in which
participants are randomly allocated to different ‘‘treatment’’
groups) called the Health Information Project: Presentation
Online (HIPPO) was initiated. Here, the researchers describe
HIPPO 2, a trial that investigates how alternative summary
statistics for communicating the reduction of CHD risk with
statins affect people’s decisions to take statins.
What Did the Researchers Do and Find? Nearly 3,000
adults in Norway and North America rated the relative
importance to them of CHD risk reduction, the cost of
statins, and the need to take a daily pill through an
interactive Web site. The researchers used these data to
calculate a ‘‘relative importance score’’ (RIS), an indicator of
each participant’s values. Each participant then decided
whether or not to take statins after being shown one of six
summary statistics about the effect of statins on CHD risk
(relative risk reduction and five indicators of absolute risk
reduction). The presentation of the effect of statins as a
relative risk reduction resulted in more people deciding to
take statins over the whole RIS range than any of the
absolute summary statistics. For every five participants
shown the relative risk reduction statistic, an extra
participant chose to take statins compared to the other
summary statistics. When asked to compare the six summary
statistics, the statistic that most people preferred and
understood best was the ‘‘natural frequency,’’ an absolute
summary statistic that gave the number of people likely to
develop CHD with and without statin treatment.
What Do These Findings Mean? Although these findings
may not be generalizable to other populations or to other
medical decisions, they provide new insights into how the
presentation of information can affect the choices people
make about health care. Specifically, these findings indicate
that the presentation of the reduced risk of getting CHD as a
result of taking stains as a relative amount is more likely to
persuade people to take statins than several absolute
summary statistics. They also suggest that the persuasive
effect of the relative risk reduction summary statistic is not
affected by the relative importance attached to the
consequences of taking statins by individuals. That is,
people shown the relative risk reduction statistic may be
more likely to start statins to reduce their CHD risk (or a drug
that reduces the risk of developing another disease)
whatever their personal values than people shown
absolute summary statistics. Finally, the findings on
participant preferences suggest that natural frequencies
may be the best summary statistic to include in tools
designed to help people make decisions about their
healthcare.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000134.
N A PLoS Medicine Editorial discusses this trial and the results
of another HIPPO trial that are presented in a separate
PLoS Medicine Research Article by Carling and colleagues;
details of a pilot HIPPO trial are also available
N The Foundation for Informed Medical Decision Making (a
US-based non-profit organization) provides information on
many aspects of medical decision making
N The Dartmouth-Hitchcock Medical Center provides infor-
mation to help people make health care decisions through
its Center for Shared Decision Making
N The Ottawa Hospital Research Institute provides also
information on patient decision aids, including an inven-
tory of decision aids available on the Web (in English and
French)
N MedlinePlus provides links to information and advice
about statins and about coronary heart disease (in English
and Spanish)
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